SREBF2 and endothelial dysfunction: These findings not only advance the understanding of the role of 12/15-LOX in atherosclerosis but also highlight the SREBP2-12/15-LOX axis as a promising therapeutic target for mitigating endothelial dysfunction and atherosclerosis under disturbed flow.